Rosh Dias, M.D., M.R.C.P.

Chief Medical Officer

Dr. Rosh Dias joined Coherus in 2022 as Chief Medical Officer. Rosh brings more than more than 20 years of pharmaceutical and biotechnology industry experience leading global, United States and rest of world teams in clinical development and medical affairs across multiple disease areas including oncology, cardiometabolic health and rare diseases. Prior to joining Coherus, he was the Chief Medical Officer at Spruce Biosciences, where he oversaw global clinical development and strategy. Prior to Spruce, Dr. Dias served as Chief Medical Officer at Indivior PLC, a global commercial pharmaceutical company focused on substance abuse and other serious mental disorders. From 2014 to 2018, Dr. Dias held senior leadership positions at Amgen, most recently as Vice President and Head of Global Scientific Affairs for all Amgen therapeutic areas, and at Amgen’s subsidiary, Onxy Pharmaceuticals, as Head of Global Medical and Scientific Affairs. Prior to Onyx, Dr. Dias worked for 10 years at Novartis Oncology in roles of increasing responsibility, including leadership roles in the global organization, the United States and in Australia, where he directed clinical development and medical affairs efforts with a focus on oncology, hematology and rare diseases. Dr. Dias holds a Medical Doctor degree from Charing Cross and Westminster Medical School in the UK, and he is a Member of the Royal College of Physicians through postgraduate qualification in Internal Medicine.

2 of 7
Rosh Dias, M.D., M.R.C.P.